Bayer Faces a Defining August as Debt Concerns and a Chinese Drug Filing Collide
Published on 07/31/2026 at 15:02 | Redaktion boerse-global.de
The calendar is crowded for Bayer. On the one hand, the Leverkusen-based conglomerate is awaiting a potentially transformative regulatory decision in China for its kidney drug Kerendia. On the other, it is bracing for a half-year earnings report that will test whether the market's generous re-rating of the stock is justified by the underlying financials.
The shares closed Thursday at EUR 48.51, up 2.10 percent on a day when European markets were broadly firmer and the DAX gained 0.60 percent to 25,612.03 points. That move came after news broke that Bayer had submitted an application to China's National Medical Products Administration (NMPA) seeking to expand Kerendia's indication to adults with non-diabetic chronic kidney disease. The filing, lodged with the regulator's Center for Drug Evaluation, is based on data from the Phase 3 FIND-CKD study, which the company completed in the spring. No timeline for a decision has been given.
The strategic logic is straightforward. Kerendia is currently approved primarily for chronic kidney disease associated with Type 2 diabetes. An expanded label would significantly enlarge the addressable patient population in one of the world's largest healthcare markets — and it would do so without requiring a new clinical trial, relying instead on existing Phase 3 evidence. For a company looking to offset revenue losses from patent expirations on older drugs, that is an attractive proposition.
The Numbers That Matter
But while the Chinese filing offers a positive narrative, the real test comes on August 4, when Bayer publishes its half-year results at 7:30 AM. The market has already priced in considerable optimism: the stock has climbed 78.17 percent over the past twelve months and sits roughly ten percent below its record high of EUR 53.86, reached in early July. Since the start of the year, the shares have advanced 30.96 percent.
Should investors sell immediately? Or is it worth buying Bayer?
The central question for investors is the trajectory of net financial debt. Bayer has guided for full-year 2026 revenue of EUR 44 to 46 billion and EBITDA before special items of EUR 9.1 to 9.6 billion. However, the planned glyphosate class-action settlement in the United States is expected to weigh heavily on cash flow. The company projects a negative free cash flow of between minus EUR 2.5 billion and minus EUR 1.5 billion, including roughly EUR 5 billion in litigation-related payments.
The consequence is that net debt is expected to rise to EUR 32 to 33 billion by year-end, up from around EUR 29.8 billion in 2025. The half-year report will reveal whether that increase is tracking the company's own guidance — or whether the burden is accumulating faster than communicated.
Two Scenarios, One Pivot Point
The technical picture supports the bullish case. At EUR 48.47, the stock trades approximately 24 percent above its 200-day moving average, signaling an intact uptrend. The relative strength index stands at 59.3, suggesting the shares are not yet overbought despite their extended run.
Yet the bearish counter-argument is equally visible. The projected rise in net debt is not a snapshot but a full-year burden, and part of it should already be visible in the half-year figures. A negative free cash flow, as Bayer itself has forecast, implies genuine financial strain even as operations stabilize. The stock's annualized 30-day volatility of 61.68 percent means the share price can react disproportionately to disappointing details — a weak division, for instance, or a stricter assessment from rating agencies.
The recent price action hints that expectations are already elevated. The stock gained 5.44 percent over the past seven trading days, suggesting some of the optimism for the reporting season has been front-loaded. If the actual numbers fall short, a pullback toward the 50-day moving average of EUR 43.05 is plausible.
Bayer at a turning point? This analysis reveals what investors need to know now.
A Broader Re-Rating
The longer-term picture remains striking. From the 52-week low of EUR 25.09, reached last August, the shares have nearly doubled. Market capitalization now stands at EUR 46.85 billion. The stock remains 9.93 percent below its 52-week high.
For investors, the Kerendia filing adds to a series of regulatory developments that position the kidney drug as one of the more important growth drivers in Bayer's pharmaceutical portfolio. China has one of the highest prevalences of chronic kidney disease globally, and an expanded approval would allow Bayer to deepen its presence there.
Still, the coming weeks are likely to be shaped more by developments in the US glyphosate litigation than by individual regulatory applications. The August 4 report will show whether the multi-month re-rating of the stock rests on solid ground — or whether the balance between earnings stabilization and rising debt is more fragile than the market has assumed.
Ad
Bayer Stock: New Analysis - 31 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
